Unmet needs

Unmet needs

Although current therapies are effective at preventing vision loss and frequently result in visual gain for patients with both Proliferative Diabetes-related Retinopathy and Diabetes-related Macular Edema, unmet treatment needs still exist. A substantial proportion (40%–50%) of eyes with Diabetes-related Macular Edema do not respond fully to anti-VEGF (VEGF=Vascular Endothelial Growth Factor; anti-VEGF therapy is the current gold standard treatment) treatment or become refractory to it, necessitating the development of novel therapies for this condition. For both Proliferative Diabetes-related Retinopathy and Diabetes-related Macular Edema, non-invasive, non-destructive, and longer-duration treatment options are also needed. Further research into the molecular pathways involved in the progression and the development of Diabetes-related Retinopathy and Diabetes-related Macular Edema may provide novel therapeutics in the future.